{
  "paper_id": "PMC7804935",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804935/",
  "figures": {
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2. Global characteristics of mCA in relation to gene mutations.",
      "caption": "a Overlap between CH cases carrying gene mutations (GMs) and chromosomal alterations (mCAs). Number of subjects are shown in black. b, c The prevalence of mCA increases with mutation burden and VAF. Observed proportion of mCAs within each subgroup is shown as solid dots; 95% CIs generated from a binomial distribution around the observed proportion are shown in blue shades. Gene mutations in regions affected by mCAs are excluded from this analysis. d Age distribution of subjects with mCA only, gene mutations only, and both types of mutations. Unadjusted P values derived from a two-ended Student’s t-test are shown. The lower and upper bounds of boxes denote 25th (Q1) and 75th (Q3) percentiles of observed ages, respectively. The lower and upper whiskers indicate the minima (Q1 − 1.5*IQR) and maxima (Q3 + 1.5*IQR). e Volcano plot of q values and odds ratios of gene representation in mCA-positive versus mCA-negative cases (Fisher’s exact test). Genes significantly enriched (FDR < 0.05) in mCA subjects are colored in red. f Frequency of gene mutations significantly enriched in subjects with mCA. Source data are provided as a Source Data file.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/238883bd595f/41467_2020_20565_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/238883bd595f/41467_2020_20565_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/238883bd595f/41467_2020_20565_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/238883bd595f/41467_2020_20565_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/238883bd595f/41467_2020_20565_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7804935/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/238883bd595f/41467_2020_20565_Fig2_HTML.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3. Patterns of co-occurrence between mCAs and gene mutations reveal diverse mechanisms of selection.",
      "caption": "a mCA events and their co-occurring gene mutations. Events are colored by alteration types. Only genes that appear more than one time are shown. b Gene loci that exhibited recurrent double hits in cis. Zoom window shows the gene loci affected and the location of the gene mutations; “2” denotes two adjacent mutations in close proximity with each other. Centromere positions are marked in gray. Gene structures are displayed below. c Pairwise associations of co-mutations between specific mCAs and gene mutations. Associations with specific chromosomal alteration types are indicated by the position of the triangle (left: AMP, top: CNLOH, right: DEL, bottom: any). FDR-corrected significance values from pairwise Fisher’s exact tests are indicated by shapes of asterisks. Odds ratios are indicated by the transparency of red shading. The chromosomal location of genes are indicated by black squares. Gene labels are colored by functional groups. Source data are provided as a Source Data file.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/e4f9af6bd6c1/41467_2020_20565_Fig3_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/e4f9af6bd6c1/41467_2020_20565_Fig3_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/e4f9af6bd6c1/41467_2020_20565_Fig3_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/e4f9af6bd6c1/41467_2020_20565_Fig3_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/e4f9af6bd6c1/41467_2020_20565_Fig3_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7804935/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b7/7804935/e4f9af6bd6c1/41467_2020_20565_Fig3_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "We show that mCAs are independent predictors of progression to hematological neoplasms and demonstrate the value of incorporating mCAs in the reporting and interpretation of CH in cancer patients22,23.Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Fortuitously, solid tumor patients increasingly undergo routine sequencing of not only tumor biopsies, but also matched blood samples as germline controls28,46 thus enabling comprehensive CH surveillance programs to be readily integrated in routine cancer care.Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "We show that mCAs are independent predictors of progression to hematological neoplasms and demonstrate the value of incorporating mCAs in the reporting and interpretation of CH in cancer patients22,23.Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Fortuitously, solid tumor patients increasingly undergo routine sequencing of not only tumor biopsies, but also matched blood samples as germline controls28,46 thus enabling comprehensive CH surveillance programs to be readily integrated in routine cancer care.Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "We show that mCAs are independent predictors of progression to hematological neoplasms and demonstrate the value of incorporating mCAs in the reporting and interpretation of CH in cancer patients22,23.Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Fortuitously, solid tumor patients increasingly undergo routine sequencing of not only tumor biopsies, but also matched blood samples as germline controls28,46 thus enabling comprehensive CH surveillance programs to be readily integrated in routine cancer care.Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "We show that mCAs are independent predictors of progression to hematological neoplasms and demonstrate the value of incorporating mCAs in the reporting and interpretation of CH in cancer patients22,23.Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Fortuitously, solid tumor patients increasingly undergo routine sequencing of not only tumor biopsies, but also matched blood samples as germline controls28,46 thus enabling comprehensive CH surveillance programs to be readily integrated in routine cancer care.Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "We show that mCAs are independent predictors of progression to hematological neoplasms and demonstrate the value of incorporating mCAs in the reporting and interpretation of CH in cancer patients22,23.Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Fortuitously, solid tumor patients increasingly undergo routine sequencing of not only tumor biopsies, but also matched blood samples as germline controls28,46 thus enabling comprehensive CH surveillance programs to be readily integrated in routine cancer care.Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "We show that mCAs are independent predictors of progression to hematological neoplasms and demonstrate the value of incorporating mCAs in the reporting and interpretation of CH in cancer patients22,23.Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Fortuitously, solid tumor patients increasingly undergo routine sequencing of not only tumor biopsies, but also matched blood samples as germline controls28,46 thus enabling comprehensive CH surveillance programs to be readily integrated in routine cancer care.Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "We show that mCAs are independent predictors of progression to hematological neoplasms and demonstrate the value of incorporating mCAs in the reporting and interpretation of CH in cancer patients22,23.Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Fortuitously, solid tumor patients increasingly undergo routine sequencing of not only tumor biopsies, but also matched blood samples as germline controls28,46 thus enabling comprehensive CH surveillance programs to be readily integrated in routine cancer care.Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "We show that mCAs are independent predictors of progression to hematological neoplasms and demonstrate the value of incorporating mCAs in the reporting and interpretation of CH in cancer patients22,23.Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Fortuitously, solid tumor patients increasingly undergo routine sequencing of not only tumor biopsies, but also matched blood samples as germline controls28,46 thus enabling comprehensive CH surveillance programs to be readily integrated in routine cancer care.Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Results\nPatient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.Implications for risk stratification\nCH mutational features obtained by NGS assays are increasingly being interpreted in the clinic to evaluate a patient’s risk of leukemic transformation20,21.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Patient cohort and samples\nThe study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The study population included 32,442 solid tumor patients (median age: 61, range 20–99, Supplementary Table 2) with non-hematologic cancers that underwent matched tumor and blood sequencing at MSKCC using the MSK-IMPACT panel28 on an institutional prospective sequencing protocol (ClinicalTrials.gov number, NCT01775072) before February 1, 2020 (Supplementary Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "The incidence of mCA increases with age, from under 1% among individuals under 50 to more than 3% among subjects who were above 80 (Fig. 1a).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel a",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We used the magnitude of deviations in logR and logOR (Methods) to estimate the aberrant cell fraction and classify events based on copy number states (Fig. 1b); 156 (47%) autosomal events were classified as deletions, 123 (37%) as CNLOH, and 56 (17%) as gains.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel b",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Among mCA individuals, 317 (92%) harbored one event, whereas 29 (8%) had multiple (range 1–4) events (Fig. 1c).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel c",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The smallest clone that we detected had an estimated cell fraction of 10% (Fig. 1d), a limit of detection comparable to prior studies based on high-density SNP-arrays without haplotype phasing (Supplementary Fig. 4)14–16.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel d",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The genomic distribution and patterns of the mCAs we detected using a targeted sequencing platform with sparse genome-wide coverage were broadly consistent with findings from high-density SNP array studies, confirming the specificity of our approach13–16 (Fig. 1e and Supplementary Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel e",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Overall, patients with mCA showed a similar blood count distribution and cytopenia incidence as ones without mCA (Supplementary Fig. 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Among different cancer types in our study, mCA was prevalent in soft tissue sarcoma, thyroid, and lung cancer patients and underrepresented in prostate and bladder cancer patients (Fig. 1f).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel f",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In a multivariable regression model, mCA was significantly associated with age (OR = 1.8, P < 0.001), male gender (OR = 1.3, P = 0.012), and white race (OR = 1.5, P = 0.033), but not smoking (OR = 1.2, P = 0.18), which was consistent with findings from prior studies16 (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "We found that mCA was positively associated with external beam radiation therapy (OR = 1.7, P = 0.022) but not cytotoxic chemotherapy (OR = 0.9, P = 0.56) (Supplementary Fig. 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 14,789 mutations were detected in 9854 (30%) individuals across 457 genes captured in our clinical sequencing assay28 (Supplementary Fig. 11a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel a",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The incidence of gene mutations increased from 5% among patients in their 20s to more than 60% in elderly patients aged above 80 (Supplementary Fig. 12b).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel b",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Among the mutation-positive patients, 6919 (70%) patients harbored a single mutation while 2935 (30%) harbored 2 or more (Supplementary Fig. 11c).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "Panel c",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "The estimated clone sizes (median 9%) of these mutations were lower than mCAs detected in this study, which reflects our higher detection sensitivity (VAF ≥ 2%) for gene mutations as compared to mCAs at low cell fractions (Supplementary Fig. 12a).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel a",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Considering both variant classes, 217 (63%) CH cases with mCAs co-occurred with at least one gene mutation captured by our panel, while 129 (37%) did not (Fig. 2a; Fisher’s exact test, OR = 3.9, P < 0.001). mCA was especially enriched in CH cases with high mutation number and VAF (Fig. 2b, c).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The age distributions for the two types of CH when found in isolation were comparable while the acquisition of both shifted towards older age (Fig. 2d).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel d",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "CH subjects with mCA had a distinct spectrum of gene mutations as compared to the remaining cohort (Fig. 2e, f).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel e",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Overall, 2% non-coding variants that co-occurred with an mCA event localized in cis with the mCA (permutation P = 0.78), whereas it is 15% for the coding variants (permutation P < 0.001; Supplementary Fig. 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This enrichment can be accounted for by mutations in seven genes that recurrently co-localized with an mCA (Fig. 3a, b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The high VAFs and the absence of 7qCNLOH events without a concurrent EZH2 mutation suggest that 7qCNLOH is a highly directed event targeting a previously acquired mutation of EZH2 in CH (Fig. 3b and Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "Additionally, we identified recurrent bi-allelic targeting of TET2 mutations by CNLOH events as well as focal deletions (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The same is true of chromosomal alterations spanning DNMT3A (deletions), ATM, and TP53 (deletions and CNLOH) (Fig. 3b).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The cellular fractions of these cis multi-hit events generally supported homozygosity of the mutant allele and shared clonal origin (Supplementary Fig. 14a).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "Panel a",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We scanned for pairwise associations of specific chromosomal alterations with genes recurrently mutated in patients with mCA (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Mutations in U2AF1, albeit rare, co-occurred with 3 out of 44 (7%) cases of 20q deletions (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We found that CH mutations in TP53 were associated with numerous chromosomal alterations (deletions in chr5, chr7, and trisomy chr3) (Fig. 3c).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel c",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In addition, we observe a significant association of TP53 mutations with the presence of multiple concomitant mCAs in CH patients (Fisher’s exact test, P = 0.0015, Supplementary Fig. 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "Interestingly, most of the subjects with recurrent CH co-mutations did not exhibit significant blood abnormalities at the time of blood draw (Supplementary Fig. 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "It is also of note that certain mCAs (e.g., chr20-, X-) frequently occurred in isolation without any clear co-mutations, indicating that these events can also drive clonal expansions alone (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Fig. 4. mCA and evolution to hematologic malignancies.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Source data are provided as a Source Data file.Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "We reviewed hospital billing records and tumor registry data and identified 96 patients with a confirmed hematological neoplasm diagnosis dated more than 3 months after blood collection (Methods, Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "Of these patients (median time to diagnosis 17 months, range 3–62 months) 26 were diagnosed with MDS, 11 with acute myeloid leukemia (AML), 7 with MPN, 4 with chronic myeloid leukemia (CML), 12 with CLL, 27 with B-cell non-Hodgkin’s lymphoma (B-NHL), 2 with T-cell non-Hodgkin’s lymphoma (T-NHL), and 7 with multiple myeloma (MM) (Fig. 4a and Supplementary Fig. 18).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Among the 96 patients who received a diagnosis, 40 (42%) had evidence of only gene mutation at the time of blood profiling, 17 (18%) had both gene mutation and mCA, whereas 1 (1%) had mCA only (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In some cases of lymphoma and MM, gene mutations in DNMT3A or TET2 were the only detected events (Fig. 4a).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Among the 5 patients with detectable mCA, both gene mutations and mCAs coincided in the same clone that seeded the corresponding hematologic neoplasms (Fig. 4b and Supplementary Fig. 19).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "Serial blood counts in 4 of the cases that subsequently developed MDS (Fig. 4b and Supplementary Fig. 19) showed that composite CH genotypes characteristic of leukemic transformation can be detected 9–39 months prior to diagnosis and before the onset of clinical-grade cytopenia43.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 19",
          "panel": "",
          "figure_key": "figure_19"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "During patient follow-up, the 3-year cumulative incidence of leukemias (MDS, MPN, AML, CML, CLL) was significantly higher in patients with composite CH genotypes (14.6%, CI: 7–22%) as compared to patients with either mCA, gene mutation PD only, or neither, of which all had a 3-year cumulative incidence of less than 1% (Fig. 4c).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel c",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We performed a multivariable cause-specific Cox regression analysis and showed that mCA was independently predictive of subsequent (>9 months post-sequencing) leukemia diagnosis (HR = 14, 95% CI: 6–33, P = 1.2e-09) after adjusting for number of mutations and VAF in PDs (Fig. 4d).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel d",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Importantly, this effect is not restricted to the subset of patients that rapidly progress to overt disease. mCA remains a statistically significant predictor among solid tumor patients who survived and did not yet experience leukemic progression in the course of their clinical care at the time of different landmarks (3, 6, 9, and 12 months post-sequencing; Supplementary Fig. 20).",
      "figure_references": [
        {
          "figure_number": "Figure 20",
          "panel": "",
          "figure_key": "figure_20"
        }
      ]
    },
    {
      "sentence": "In addition, we obtain similar risk estimates for gene mutations and mCA after restricting the analysis to patients with no blood abnormalities at the time of CH assessment (Supplementary Fig. 21).",
      "figure_references": [
        {
          "figure_number": "Figure 21",
          "panel": "",
          "figure_key": "figure_21"
        }
      ]
    },
    {
      "sentence": "Methods\nMSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "MSK-IMPACT cohort\nThe study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    },
    {
      "sentence": "The study population included patients with non-hematologic cancers at MSKCC that underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol ClinicalTrials.gov number, NCT01775072 before February 1, 2020 (Supplementary Fig. 1); all patients enrolled on this protocol provided informed consent in written form.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Subjects who had a billing code related to hematologic malignancy prior to, or less than 3 months after the time of blood draw were excluded (Supplementary Fig. 17).",
      "figure_references": [
        {
          "figure_number": "Figure 17",
          "panel": "",
          "figure_key": "figure_17"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 461,
    "images_downloaded": 2,
    "tables_filtered": 4
  }
}